Weiqun Mao

1.2k total citations
33 papers, 896 citations indexed

About

Weiqun Mao is a scholar working on Molecular Biology, Epidemiology and Oncology. According to data from OpenAlex, Weiqun Mao has authored 33 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 13 papers in Epidemiology and 12 papers in Oncology. Recurrent topics in Weiqun Mao's work include Autophagy in Disease and Therapy (13 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer-related Molecular Pathways (7 papers). Weiqun Mao is often cited by papers focused on Autophagy in Disease and Therapy (13 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer-related Molecular Pathways (7 papers). Weiqun Mao collaborates with scholars based in United States, China and United Kingdom. Weiqun Mao's co-authors include Robert C. Bast, Zhen Lü, Xiao‐Feng Le, Angela Thornton, Hailing Yang, Xiao-Feng Le, Gong Yang, Jinyun Liu, Margie N. Sutton and Bing Z. Carter and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and PLoS ONE.

In The Last Decade

Weiqun Mao

32 papers receiving 886 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Weiqun Mao United States 20 546 310 217 165 105 33 896
Barry Jutten Netherlands 17 442 0.8× 209 0.7× 266 1.2× 192 1.2× 57 0.5× 19 804
Sanjeev Das India 19 668 1.2× 415 1.3× 268 1.2× 134 0.8× 42 0.4× 36 1.1k
Edwardine Nodzenski United States 14 613 1.1× 225 0.7× 185 0.9× 99 0.6× 86 0.8× 22 916
Sherry A. Weppler Netherlands 10 504 0.9× 144 0.5× 307 1.4× 225 1.4× 57 0.5× 11 836
JEFF EVANS United Kingdom 6 617 1.1× 397 1.3× 278 1.3× 98 0.6× 62 0.6× 24 1.2k
Constantinos Alifieris Greece 7 400 0.7× 334 1.1× 216 1.0× 89 0.5× 65 0.6× 15 998
Sriparna Ghosh United States 12 372 0.7× 225 0.7× 238 1.1× 125 0.8× 47 0.4× 16 717
Alisha M. Mendonsa United States 7 478 0.9× 268 0.9× 227 1.0× 108 0.7× 25 0.2× 8 865
Edward Curry United Kingdom 17 659 1.2× 161 0.5× 244 1.1× 56 0.3× 118 1.1× 31 1.1k

Countries citing papers authored by Weiqun Mao

Since Specialization
Citations

This map shows the geographic impact of Weiqun Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiqun Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiqun Mao more than expected).

Fields of papers citing papers by Weiqun Mao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiqun Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiqun Mao. The network helps show where Weiqun Mao may publish in the future.

Co-authorship network of co-authors of Weiqun Mao

This figure shows the co-authorship network connecting the top 25 collaborators of Weiqun Mao. A scholar is included among the top collaborators of Weiqun Mao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiqun Mao. Weiqun Mao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guo, Jinghui, Hailing Yang, Gamze Bildik, et al.. (2025). DIRAS3 Inhibits Ovarian Cancer Cell Growth by Blocking the Fibronectin-Mediated Integrin β1/FAK/AKT Signaling Pathway. Cells. 14(16). 1250–1250.
2.
Blessing, Alicia M., Weiqun Mao, Lan Pang, et al.. (2020). Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. Cancer. 126(15). 3579–3592. 13 indexed citations
3.
Sutton, Margie N., Gilbert Y. Huang, Xiaowen Liang, et al.. (2019). DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. Cancers. 11(4). 557–557. 19 indexed citations
4.
Yang, Hailing, Weiqun Mao, Cristian Rodriguez‐Aguayo, et al.. (2018). Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clinical Cancer Research. 24(20). 5072–5084. 32 indexed citations
5.
Zhou, Jinhua, Shu Zhang, Abdulkhaliq Alsaadi, et al.. (2016). A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Clinical Cancer Research. 23(8). 1945–1954. 48 indexed citations
6.
Ornelas, Argentina, Zhen Lü, Niki M. Zacharias, et al.. (2016). Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer. 16(1). 824–824. 24 indexed citations
7.
Orozco, Aaron, Margie N. Sutton, Hailing Yang, et al.. (2015). ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death and Disease. 6(8). e1836–e1836. 51 indexed citations
8.
Zhang, Shu, Zhen Lü, Weiqun Mao, et al.. (2015). CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS ONE. 10(7). e0131833–e0131833. 29 indexed citations
9.
Yang, Hailing, Partha Das, Yinhua Yu, et al.. (2015). NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget. 7(3). 3018–3032. 11 indexed citations
10.
Stellrecht, Christine M., Hima V. Vangapandu, Xiao-Feng Le, Weiqun Mao, & Shujun Shentu. (2014). ATP directed agent, 8-chloro-adenosine, induces AMP activated protein kinase activity, leading to autophagic cell death in breast cancer cells. Journal of Hematology & Oncology. 7(1). 23–23. 30 indexed citations
11.
Le, Xiao‐Feng, Maria Inês Almeida, Weiqun Mao, et al.. (2012). Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. PLoS ONE. 7(7). e41170–e41170. 58 indexed citations
12.
Le, Xiao-Feng, Weiqun Mao, Guangan He, et al.. (2011). The Role of p27 Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. JNCI Journal of the National Cancer Institute. 103(18). 1403–1422. 23 indexed citations
13.
Le, Xiao‐Feng, Weiqun Mao, Zhen Lü, Bing Z. Carter, & Robert C. Bast. (2010). Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 116(21). 4980–4990. 71 indexed citations
14.
Samanta, Ajoy K., Helen J. Huang, Xiao‐Feng Le, et al.. (2009). MEKK3 expression correlates with nuclear factor κ B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer. 115(17). 3897–3908. 23 indexed citations
15.
Le, Xiao-Feng, Weiqun Mao, Chunhua Lu, et al.. (2008). Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle. 7(23). 3747–3758. 45 indexed citations
16.
17.
Le, Xiao-Feng, Weiqun Mao, Zhen Lü, et al.. (2006). Anti-HER2 Antibody Trastuzumab Inhibits CDK2-Mediated NPAT and Histone H4 Expression via PI3K Pathway. Cell Cycle. 5(15). 1654–1661. 20 indexed citations
18.
19.
Le, Xiao‐Feng, Weiqun Mao, Isabelle Bedrosian, et al.. (2005). Growth arrest induced by anti-HER2 antibody blocks breast cancer cells in the late G1 phase of the cell cycle. Cancer Research. 65. 533–533. 5 indexed citations
20.
Le, Xiao‐Feng, David Gold, Yiling Lu, et al.. (2004). Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling. Journal of Biological Chemistry. 280(3). 2092–2104. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barry Jutten Breakdown of academic impact, for papers by Sanjeev Das Breakdown of academic impact, for papers by Edwardine Nodzenski Breakdown of academic impact, for papers by Sherry A. Weppler Breakdown of academic impact, for papers by JEFF EVANS Breakdown of academic impact, for papers by Constantinos Alifieris Breakdown of academic impact, for papers by Sriparna Ghosh Breakdown of academic impact, for papers by Alisha M. Mendonsa Breakdown of academic impact, for papers by Edward Curry
Rankless by CCL
2026